Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
97 hedge funds and large institutions have $746M invested in Akero Therapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 33 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
20.92% more ownership
Funds ownership: 80.3% → 101.23% (+21%)
19% more capital invested
Capital invested by funds: $626M → $746M (+$120M)
9% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 33
6% less funds holding
Funds holding: 103 → 97 (-6)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
99% less call options, than puts
Call options by funds: $12K | Put options by funds: $1.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$38.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.99M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.99M |
| 4 |
BlackRock
New York
|
+$1.72M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$932K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$24.1M |
| 2 |
KPW
Kore Private Wealth
New York
|
-$6.83M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.35M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$4.02M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.69M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SAM
101
Stansberry Asset Management
Westlake,
Texas
| – | -$489K | -21,883 | Closed |
|
|
WG
102
Winton Group
London,
United Kingdom
| – | -$365K | -16,330 | Closed |
|
103
Simplex Trading
Chicago,
Illinois
| – | -$258K | -11,642 | Closed |
|
|
PPA
104
Parametric Portfolio Associates
Seattle,
Washington
| – | -$207K | -9,254 | Closed |
|
|
NFGH
105
Nan Fung Group Holdings
Kai Tak,
Hong Kong
| – | -$78K | -3,470 | Closed |
|
|
PCM
106
Penserra Capital Management
Orinda,
California
| – | -$17K | -800 | Closed |
|
|
PHK
107
Point72 Hong Kong
Hong Kong
| – | -$15K | -650 | Closed |
|
|
EWA
108
Evolution Wealth Advisors
Aventura,
Florida
| – | -$5K | -211 | Closed |
|
|
JMF
109
Johnson Midwest Financial
Glidden,
Iowa
| – | -$2K | -103 | Closed |
|
|
RE
110
RBC Europe
London,
United Kingdom
| – | -$2.23K | -100 | Closed |
|
|
GWM
111
Geneos Wealth Management
Englewood,
Colorado
| – | -$1K | -50 | Closed |
|
|
TFA
112
Toth Financial Advisory
Leesburg,
Virginia
| – | -$1K | -50 | Closed |
|
|
S
113
SignatureFD
Atlanta,
Georgia
| – | -$1K | -48 | Closed |
|
AKRO Hedge Fund Activity: Q4 2021 in Review
97 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q4 2021, worth a combined $746M — up 19% from $626M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AKRO and 11 opened new positions — a net loss of 5 holders — while 33 trimmed existing stakes and 30 added.
The largest buyer was Goldman Sachs, adding an estimated $38.5M. The largest seller was Redmile Group, cutting an estimated $24.1M.
- 97 institutional investors held Akero Therapeutics (AKRO) as of Q4 2021, down from 103 in Q3 2021.
- Funds reported $746M of Akero Therapeutics stock for Q4 2021, up 19% quarter-over-quarter.
- 11 funds opened new Akero Therapeutics positions in Q4 2021 and 16 closed out, a net change of -5 holders.
- The largest Akero Therapeutics buyer in Q4 2021 was Goldman Sachs, an estimated $38.5M added.
- The largest Akero Therapeutics seller in Q4 2021 was Redmile Group, an estimated $24.1M sold.
Based on aggregated 13F filings for Q4 2021.